Eisai submits lenvatinib NDA, MAA

Eisai Co. Ltd. (Tokyo:4523) submitted an NDA to FDA and an MAA to EMA seeking approval of lenvatinib ( E7080) to treat progressive, radioiodine-refractory differentiated thyroid cancer. Late last mont...